If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
14,240.00    -124.00 (-0.86%)
Bid:
14,192.00
Ask:
14,194.00
Spread: 2.00 (0.014%)
Market Cap: £220.84b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Stabilisation Notice

10 Jun 2021 11:32

RNS Number : 5097B
Morgan Stanley & Co. Int'l plc
10 June 2021
 

 

10 June 2021

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

AstraZeneca PLC

Post-stabilisation Period Announcement

Further to the pre-stabilisation period announcement dated 26 May 2021, Morgan Stanley & Co. International plc as Coordinating Stabilisation Manager (contact: Morgan Stanley Debt Syndicate - Daniel Shane; telephone:+44 20 7677-7070) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the EU Market Abuse Regulation (596/2014),as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.

Issuer:

AstraZeneca PLC

Guarantor (if any):

N/A

ISIN:

XS2347663507

Aggregate nominal amount:

EUR 800,000,000

Description:

EUR 800,000,000 0.375 per cent. Notes due 2029

Stabilisation Manager(s):

Morgan Stanley & Co. International plc

Goldman Sachs International

J.P. Morgan Securities plc

Offer price:

99.584%

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

This announcement is not an offer of securities for sale into the United States. The securities referred to above have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There has not been and will not be a public offer of the securities in the United States.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAFMMMTMTJBBBB
Date   Source Headline
29th Jul 20257:00 amRNSH1 and Q2 2025 results
24th Jul 20257:00 amRNSGefurulimab nanobody met Phase III endpoints
22nd Jul 20257:00 amRNSAstraZeneca plans to invest $50bn in the US
16th Jul 20257:00 amRNSUpdate on anselamimab in AL amyloidosis
14th Jul 20257:00 amRNSBaxdrostat met primary endpt in BaxHTN PhIII trial
4th Jul 20257:00 amRNSImfinzi approved in the EU for bladder cancer
1st Jul 20253:00 pmRNSTotal Voting Rights
24th Jun 20257:00 amRNSDatroway approved in US for EGFRm lung cancer
17th Jun 202511:45 amRNSHolding(s) in Company
13th Jun 20259:30 amRNSAstraZeneca enters into collaboration with CSPC
12th Jun 20253:00 pmRNSDirector/PDMR Shareholding
6th Jun 20257:00 amRNSFixed-duration Calquence approved in EU for 1L CLL
2nd Jun 20253:05 pmRNSBlock listing Interim Review
2nd Jun 20253:00 pmRNSTotal Voting Rights
27th May 20257:00 amRNSImfinzi recommended in EU for bladder cancer
23rd May 202510:00 amRNSDirector/PDMR Shareholding
21st May 20251:45 pmRNSDirector Declaration
20th May 20257:00 amRNSAcquisition of EsoBiotec completed
9th May 20257:00 amRNSImfinzi improved DFS in early bladder cancer
7th May 20257:30 amRNSEnhertu improved pCR in early-stage breast cancer
6th May 20257:00 amRNSCalquence combination approved in EU for 1L MCL
2nd May 20257:00 amRNSBreztri met primary endpoints in Ph3 asthma trials
1st May 20254:00 pmRNSDirector/PDMR Shareholding
1st May 20253:00 pmRNSTotal Voting Rights
29th Apr 20257:10 amRNSFixed-duration Calquence recommended in EU for CLL
29th Apr 20257:05 amRNSUpdate on CAPItello-280 Phase III trial
29th Apr 20257:00 amRNS1st Quarter Results
22nd Apr 20257:00 amRNSEnhertu combination improved PFS in 1L HER2+ mBC
11th Apr 20255:30 pmRNSResult of AGM
4th Apr 20257:05 amRNSImfinzi approved in EU for AEGEAN
4th Apr 20257:00 amRNSEnhertu approved in EU in post-ET breast cancer
1st Apr 20253:00 pmRNSTotal Voting Rights
31st Mar 20257:05 amRNSCalquence recommended for EU approval in 1L MCL
31st Mar 20257:00 amRNSImfinzi approved in the US for bladder cancer
21st Mar 202510:58 amRNSAZN invests $2.5bn in Beijing R&D & manufacturing
17th Mar 20257:10 amRNSEneboparatide Phase III trial met primary endpoint
17th Mar 20257:05 amRNSImfinzi approved in EU for limited-stage SCLC
17th Mar 20257:00 amRNSAstraZeneca to acquire EsoBiotec
12th Mar 20256:00 pmRNSHolding(s) in Company
7th Mar 20253:00 pmRNSDirector/PDMR Shareholding
7th Mar 202511:00 amRNSNotice of AGM
7th Mar 20257:00 amRNSImfinzi improved EFS in early-stage gastric cancer
6th Mar 20253:00 pmRNSDirector/PDMR Shareholding
5th Mar 20253:00 pmRNSDirector/PDMR Shareholding
3rd Mar 20253:00 pmRNSTotal Voting Rights
3rd Mar 20257:00 amRNSImfinzi recommended for EU approval for AEGEAN
28th Feb 20251:00 pmRNSEnhertu recommended in EU in post-ET breast cancer
26th Feb 20257:00 amRNSCamizestrant improved PFS in 1L HR+ breast cancer
19th Feb 20257:00 amRNSFiling of Form 20-F with SEC
18th Feb 20252:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.